Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M9.0Revenue (TTM) $M0.5Net Margin (%)-12,391.2Altman Z-Score-26.6
Enterprise Value $M14.4EPS (TTM) $-1.5Operating Margin %-16,454.9Piotroski F-Score3
P/E(ttm)--Beneish M-Score-10.4Pre-tax Margin (%)-12,391.2Higher ROA y-yY
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio1.5Cash flow > EarningsY
Price/Sales12.35-y EBITDA Growth Rate %-56.0Current Ratio1.5Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-91.7Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M55.0ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with ARGS

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

ARGS is held by these investors:



ARGS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Pharmstandard International S.10% Owner 2016-10-07Buy31,704$4.73-96.62view
Pharmstandard International S.10% Owner 2016-09-29Buy43,618$4.56-96.49view
Pharmstandard International S.10% Owner 2016-09-20Buy46,839$4.77-96.65view
Pharmstandard International S.10% Owner 2016-09-16Buy52,512$4.77-96.65view
Pharmstandard International S.10% Owner 2016-09-01Buy16,977$4.78-96.65view
Pharmstandard International S.10% Owner 2016-08-24Buy67,371$4.52-96.46view
Pharmstandard International S.10% Owner 2016-08-24Buy55,224$4.57-96.5view
Pharmstandard International S.10% Owner 2016-08-22Buy75,474$4.24-96.23view
Winterbottom JoanChief Human Resources Officer 2015-12-16Buy250$1.83-91.26view
Petrov Andrei VladimirovichDirector 2015-12-16Buy5,000$1.8-91.11view

Press Releases about ARGS :

Quarterly/Annual Reports about ARGS:

    News about ARGS:

    Articles On GuruFocus.com
    Argos Therapeutics Announces Appointment of Richard Morrison, PhD to Board of Directors Sep 26 2017 
    Argos Therapeutics to Hold Conference Call to Discuss Update on the Phase 3 ADAPT Trial Presented at Sep 19 2017 
    Argos Therapeutics Reports on Interim Analysis of Phase 3 ADAPT Trial Presented at ESMO 2017 Congres Sep 12 2017 
    Argos Announces First Dosing of HIV Patient with AGS-004 Derived from the Latent Viral Reservoir Sep 06 2017 
    Argos Therapeutics Announces Interim Analysis of Phase 3 ADAPT Trial to be Presented at ESMO 2017 Co Aug 21 2017 
    Argos Reports Immunogenicity Results of AGS-004 in HIV Program Jul 26 2017 
    Argos Therapeutics Announces Closing of $6.0 Million Secured Convertible Note Financing Jun 22 2017 
    Argos Therapeutics Announces $6,000,000 Secured Convertible Note Financing Jun 16 2017 
    Argos Provides Update on its ADAPT Trial Following Meeting with FDA May 10 2017 
    SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,0 May 09 2017 
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

    GF Chat

    {{numOfNotice}}
    FEEDBACK